Home » Topics » BioWorld Science

BioWorld Science
RSS

New REPAIR-MS phase II study begins with CNM-Au8 for MS

Jan. 13, 2020

Seelos reports interim phase I data on intranasal racemic ketamine

Jan. 13, 2020

ContraFect begins dosing in phase III study of exebacase for S. aureus bacteremia

Jan. 13, 2020

AKCEA-TTR-LRx begins phase III cardiovascular outcomes study

Jan. 13, 2020

Bio-Thera launches adalimumab biosimilar Qletli in China

Jan. 13, 2020

Xuanzhu (Hainan) Biopharmaceutical identifies farnesoid X receptor agonists

Jan. 13, 2020

New NRTK1 inhibitors disclosed by Beijing Innocare Pharmaceutical Technology

Jan. 13, 2020

Treatment effects may spread in LCA gene therapy

Jan. 13, 2020

Merck & Co. discovers PCSK9 inhibitors

Jan. 13, 2020

Amyloid after amnesia?

Jan. 13, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...